Although reductions in SV2A expression have been consistently documented in AD-affected brain tissue [36], the precise pathophysiological role of this protein, its mechanistic involvement in disease progression, and the pharmacokinetic properties of existing SV2A-targeted radioligands remain incompletely characterized and require further investigation [35]. The gene discussed is SV2A; the disease is Alzheimer disease.